Concord Drugs Balance Sheet Health
Financial Health criteria checks 2/6
Concord Drugs has a total shareholder equity of ₹338.8M and total debt of ₹190.9M, which brings its debt-to-equity ratio to 56.3%. Its total assets and total liabilities are ₹732.6M and ₹393.8M respectively. Concord Drugs's EBIT is ₹12.1M making its interest coverage ratio 0.7. It has cash and short-term investments of ₹535.0K.
Key information
56.3%
Debt to equity ratio
₹190.94m
Debt
| Interest coverage ratio | 0.7x |
| Cash | ₹535.00k |
| Equity | ₹338.84m |
| Total liabilities | ₹393.79m |
| Total assets | ₹732.64m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 538965's short term assets (₹595.6M) exceed its short term liabilities (₹332.6M).
Long Term Liabilities: 538965's short term assets (₹595.6M) exceed its long term liabilities (₹61.1M).
Debt to Equity History and Analysis
Debt Level: 538965's net debt to equity ratio (56.2%) is considered high.
Reducing Debt: 538965's debt to equity ratio has increased from 42.1% to 56.3% over the past 5 years.
Debt Coverage: 538965's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 538965's interest payments on its debt are not well covered by EBIT (0.7x coverage).